Jan 31, 2023 Legal Lingo: Real estate funds 101 By Isuri De Alwis Being an aspiring commercial lawyer often means being confronted by complex, often abstract, concepts leading to an often impenetrable...
Jan 30, 2023 Making the transition from medical devices to medtech By Hannah Kerr-Peterson Edward Machin Robert Lister David Dowling +1 more... Show less Our handling of, and emergence from, the COVID-19 pandemic has, in no small part, been due to the many significant advances made by big...
Jan 30, 2023 UK poised to finalise “failure to prevent fraud” offence By Paige Berges The United Kingdom has pioneered corporate “failure to prevent” offences in the context of the UK Bribery Act 2010 (UKBA) and the...
Jan 27, 2023 UK consultation on R&D tax relief raises questions for life sciences By David Dowling Sophie Waters As we have discussed in recent posts, the UK Government has set its hopes for growth on becoming a ‘science superpower’. A key part of...
Jan 25, 2023 Life sciences - key developments to expect in 2023 and beyond By Lincoln Tsang A recently published alert, which can be found here, provides a reflection of the challenges and the growth-driving opportunities...
Jan 25, 2023 What drives a successful GP-LP relationship? By Isabel Dische I recently sat down with my asset management colleagues, Emily Brown in London, and Vince Ip and Chune Loong Lum in Hong Kong, to...
Jan 24, 2023 Cybersecurity - private equity firms sharpen their focus By Catherine Keeling Cybersecurity has become an increasingly regulated area of risk for many businesses in the digital world. As technology has advanced and...
Jan 19, 2023 Metamorphosis of contractual necessity as a lawful basis of processing under the GDPR By Christopher Foo Under the GDPR, the processing of personal data requires a lawful basis. These include, among others, the processing of data: with the...
Jan 19, 2023 European restructuring & insolvency – what we saw in 2022 and what to expect in 2023 By Matthew Czyzyk Samuel Norris Natalie Blanc Emily Ma Ana Biloglav +2 more... Show less As 2023 gets underway, we've taken the opportunity here to look at what we saw in the European distressed market in 2022, as well as...
Jan 18, 2023 Private funds – what we expect to see in 2023 By Tom Alabaster Emily Brown Alex Chauvin Lavanya Raghavan Chris Townsend +2 more... Show less As we start the New Year, we look ahead at trends we expect to see in the private fundraising space. According to data from Preqin in...
Jan 18, 2023 Private equity investment: Trends to expect in 2023 By Angela Becker Helen Croke Shona Ha Victoria McGrath John Newton Dan Oates Simon Saitowitz Elizabeth Todd +5 more... Show less In contrast to the remarkable levels of deal activity seen in 2021, the last 12 months have been more challenging for private equity...
Jan 18, 2023 Tick, tock: countdown begins to EU cyber laws By Edward Machin Two years can feel like a long time, but it’s really not. The Beatles released Help!, Rubber Soul, Revolver and Sgt. Pepper’s Lonely...
Jan 17, 2023 A guide on key legal issues facing PE deal makers in the UK By Shona Ha The UK Chapter of The Legal 500: Private Equity Comparative Guide 2023 – authored by private equity transaction partners John Newton and...
Jan 16, 2023 Legal Lingo: What is a syndicated loan? By Alexandra Street Being an aspiring commercial lawyer often means being confronted by complex, often abstract, concepts leading to an often impenetrable...
Jan 16, 2023 A year of the NSIA – The good, the bad and the ugly By Annie Herdman Kabya Chaharia The UK's National Security and Investment Act 2021 (NSIA) – the UK equivalent of CFIUS – entered into force on January 4, 2022 and...
Jan 16, 2023 Reflections for dealmakers from JPMorgan Healthcare Conference 2023 By David Dowling As everyone unpacks from last week's JPMorgan Healthcare Conference 2023 and digests their various meetings, it is worth reflecting on...